In Brief: Hydrochlorothiazide and Skin Cancer

Date: November 16, 2020
Issue #: 
1611Summary: 
The FDA has required the addition of information about
an increased risk of nonmelanoma skin cancer (basal
cell carcinoma [BCC] and squamous cell carcinoma
[SCC]) to the labels of products containing the diuretic
hydrochlorothiazide.

Source: The Medical Letter - October 27, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research